TP53 and cancer: This feature distinguishes the anti-L1 antibody response from that of other autoantibodies considered as potential cancer biomarkers, which are limited in their value for early cancer detection because they are more commonly associated with advanced stages of disease [e.g., to p53, heat shock proteins, etc. (54)].